Full-Time
Senior Clinical Research Associate 2
Oncology
Posted on 5/12/2026
Fortrea
10,001+ employees
Global CRO managing phase I–IV trials
Compensation Overview
$115k - $140k/yr
New Mexico, USA + 9 more
More locations: Washington, USA | Oregon, USA | California, USA | Montana, USA | Nevada, USA | Arizona, USA | Colorado, USA | Utah, USA | Idaho, USA
Remote
West Coast focus; 60-70% overnight travel; remote in US.
 Biology & Biotech (1) |
|---|
- University or college degree, or certification in a related allied health profession from an appropriately accredited institution (e.g. nursing licensure)
- 4+ years of Clinical Monitoring experience
- Oncology experience is required
- 60-70% overnight travel
- Responsible for all aspects of study site monitoring including routine monitoring and close-out of clinical sites, maintenance of study files, conduct of pre-study and initiation visits; liaise with vendors; and other duties, as assigned
- Responsible for all aspects of site management as prescribed in the project plans
- General On-Site Monitoring
- Ensure the study staff who will conduct the protocol have received the proper materials and instructions to safely enter patients into the study
- Ensure the protection of study patients by verifying that informed consent procedures and protocol requirements are adhered to according to the applicable regulatory requirements
- Ensure the integrity of the data submitted on Case Report Forms (CRFs) or other data collection tools by careful source document Monitor data for missing or implausible data
- Responsible for all aspects of registry management as prescribed in the project plans - Undertake feasibility work when requested
- Complete Serious Adverse Event (SAE) reporting, process production of repo11s, narratives and follow up of SAEs
- Independently perform CRF review; query generation and resolution against established data review guidelines on Fortrea or client data management systems as assigned by management
- Assist with training of new employees, eg. co-monitoring
- Coordinate designated clinical projects as a Local Project Coordinator (with supervision, if applicable) and may act as a local client contact as assigned
- Perform other duties as assigned by management
- None
Fortrea is a global contract research organization (CRO) that provides clinical trial management, clinical pharmacology services, and consulting for pharmaceutical, biotechnology, and medical device companies. It runs Phase I–IV trials, operates its own clinical trial sites, and handles patient recruitment including healthy volunteers and patients with specific conditions. It offers mobile clinical solutions to improve patient retention and adherence and tailors its services to each client’s needs, generating revenue from fees for research and development services. Fortrea aims to streamline the clinical trial process and support innovation in its clients' trials by delivering customized, end-to-end trial delivery solutions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
2023
Simplify's Take
What believers are saying
- FIT platform expansion across clinical pharmacology, development, and medical devices drives revenue.
- Strong biotech activity and three consecutive quarters above 1.1x book-to-bill sustains growth.
- Over $0.5 billion liquidity enables strategic investments and debt reduction initiatives.
What critics are saying
- IQVIA's superior AI platform erodes Fortrea's biotech bookings within 12-18 months.
- Customer concentration exposes Fortrea to 15-20% revenue loss from single contract.
- PPD and ICON undercut Fortrea's functional services pricing, compressing margins significantly.
What makes Fortrea unique
- Fortrea Intelligent Technology suite automates clinical trial workflows with AI-powered analytics.
- Book-to-bill ratio of 1.15x in Q1 2026 signals strong biotech demand momentum.
- Adjusted EBITDA surged 55% year-over-year to $47 million through operational efficiency.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Fortrea who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Vacation
Company News
Fortrea unveils Fortrea Intelligent Technology(TM) to help sponsors and sites run Smarter, more integrated trials. Fortrea Holdings Inc AI-enhanced suite of solutions features new and improved technology to empower efficiency, confidence and quality. Highlights: * Designed to transform clinical trial operations for sponsors, sites and study teams * Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and quality * Builds on Fortrea's flagship platform Xcellerate(R) to deliver near-real-time, role-based insights DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) - Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology(TM)(FIT), a suite of innovative technology solutions designed to transform clinical trial operations. By integrating persona-driven, AI-powered solutions that automate workflows, streamline oversight and elevate productivity, FIT helps enable sponsors, investigator sites and Fortrea project teams to deliver trials faster, with greater predictability, agility and quality. An Innovative, Intelligent Suite of Clinical Solutions FIT encompasses major enhancements to familiar Fortrea offerings, including the award-winning Xcellerate(R) platform, along with newly launched solutions designed to integrate all processes within the trial ecosystem. The suite boasts applications for biopharma and biotech customers across clinical pharmacology, clinical development and medical device development, and it can be deployed in both full service and functional service models, with select components available as software-as-a service (SaaS). FIT solutions are arranged into three pillars: * Lifecycle: Deliver Trials Faster with Confidence Solutions that help sponsors and sites progress clinical trials throughout each step of the clinical development journey. They help accelerate clinical trials by automating key steps, from pre-award to final eTMF. * Foresight: Turn Data into Actionable Insights Solutions that transform data into foresight, helping enable faster decision-making and proactive risk mitigation. They provide clarity, trend analysis and risk mitigation through intuitive dashboards that empower confident, near-real-time decisions and simplified oversight. * Companion: Empowering Study Teams to Work Smarter Persona-driven, AI-powered solutions that support more productive and efficient clinical trial operations. They help streamline study delivery, help boost productivity and enable collaboration. "We are at a remarkable moment in time, where the evolution of clinical trials is converging with unprecedented advancements in technology. Fortrea Intelligent Technology sits at this nexus," said Chief Information Officer Alejandro Martinez Galindo. "Built on decades of industry experience and direct sponsor and investigator site input, FIT delivers human-centered solutions that enable sponsors and sites to conduct trials more efficiently, with greater confidence and lower risk." Xcellerate(R) Anchors the Intelligent Suite Xcellerate(R), Fortrea's platform for Risk-Based Quality Management (RBQM), Central Monitoring and Oversight, is the foundation of the FIT offering. Recent enhancements deliver a modern, intuitive experience that integrates data across the trial ecosystem to provide near-real-time, role-based insights. With embedded AI and machine learning, Xcellerate(R) can analyze complex patterns, generate predictive signals and initiate automated workflows, reducing manual effort and enabling teams to focus on the critical human judgment required for successful clinical research. "We expect these Xcellerate(R) enhancements and the broader FIT platform will be game changers for our study teams and our clients," said Chief Operating Officer and President, Clinical Development Mark Morais. "Incorporating the responsible and ethical use of AI, these technologies enable a stronger research ecosystem and the ability to respond more quickly to what the data are telling us - all of which can make the difference in getting life-changing treatments to patients faster and more efficiently." Fortrea continues to expand the Fortrea Intelligent Technology portfolio, with additional solutions planned for future release. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. Connectweb partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Its talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow Connectweb on LinkedIn, X and Bluesky. Fortrea Contacts: Jennifer Minx (Media) - 919-410-4195, [email protected] Kate Dillon (Media) - 646-818-9115, [email protected] Tracy Krumme (Investors) - 984-385-6707, [email protected]
Fortrea, a global clinical research organisation, has unveiled Fortrea Intelligent Technology (FIT), an AI-enhanced suite of solutions designed to transform clinical trial operations for sponsors, sites and study teams. The platform builds on Fortrea's Xcellerate system to deliver persona-driven, AI-powered solutions that automate workflows and streamline oversight. FIT is organised into three pillars: Lifecycle, which accelerates trials from pre-award to final eTMF; Foresight, providing near-real-time insights and risk mitigation through intuitive dashboards; and Companion, offering AI-powered tools to boost productivity and collaboration. The suite is available for clinical pharmacology, clinical development and medical device development, deployable in full service and functional service models, with select components available as software-as-a-service.
Fortrea reported Q4 revenue of $660.5 million, down 5.2% year-over-year, and full-year revenue of $2.723 billion, up 1% and within guidance. Q4 adjusted EBITDA was $54 million, whilst full-year adjusted EBITDA reached $189.9 million. The company posted a Q4 GAAP net loss of $32.5 million. Management noted improving demand, with Q4 book-to-bill at 1.14x and backlog at $7.7 billion, driven by higher client engagement and increased biotech RFP flow. Fortrea exceeded cost-savings targets, delivering $153 million gross savings, and generated strong Q4 operating cash flow of $129.1 million. The company repurchased $75.7 million of senior notes and ended with over $600 million liquidity. For 2026, Fortrea guided revenue of $2.55–2.65 billion with adjusted EBITDA of $190–220 million.
Clinical research company Fortrea Holdings reports Q4 earnings tomorrow. Analysts expect revenues to decline 4.3% year on year, following a 1.8% decrease in the same quarter last year. Last quarter, Fortrea beat revenue expectations with $701.3 million, up 3.9% year on year, and issued full-year guidance exceeding analysts' forecasts. However, the company has missed Wall Street's revenue estimates multiple times over the past two years. Analysts have largely maintained their estimates over the last 30 days. Shares have declined 36.8% over the past month, underperforming the drug development inputs and services segment, which averaged a 1.1% decline. The stock currently trades at $10.98 against an average analyst price target of $16.44.
Fortrea, a global contract research organisation, has expanded its executive team with two appointments. Oren Cohen, who previously served as both chief medical officer and president of Clinical Pharmacology Services, will now focus solely on his CMO responsibilities, overseeing medical strategy, scientific leadership and governance across Fortrea's portfolio. Scott Dove has joined as president of Clinical Pharmacology Services, responsible for early clinical development solutions across Fortrea's global network. Dove brings over 25 years of drug development experience, most recently serving as chief operating officer at Aravive and holding leadership roles at PPD, Allergan and Furiex Pharmaceuticals. Both Cohen and Dove serve on Fortrea's Executive Committee. The company provides clinical trial management and consulting services across more than 20 therapeutic areas.